Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome

Clinical Science

Volumn 118, Issue 1, 2010, Pages 79-85

  Ng, Theodore W K ^a   Chan, Dick C ^a   Barrett, P Hugh R ^a   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Apolipoprotein; Cardiovascular disease; Dietary restriction; Lipoprotein kinetics; Obesity; Weight loss

Indexed keywords

APOLIPOPROTEIN A2; HIGH DENSITY LIPOPROTEIN;

ARTICLE; BODY MASS; CATABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANTHROPOMETRY; APOLIPOPROTEIN A-II; BODY COMPOSITION; BODY MASS INDEX; DIET, FAT-RESTRICTED; DIET, REDUCING; HUMANS; INSULIN RESISTANCE; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; WEIGHT LOSS;

EID: 70549084742     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090110     Document Type: Article

References (28)

1. Grundy, S. M. (2007) Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 92, 399-404
2. Alexander, C. M., Landsman, P. B., Teutsch, S. M. and Haffner, S. M. (2003) NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52, 1210-1214
3. Rader, D. J. (2007) Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat. Clin. Pract. Cardiovasc. Med. 4, 102-109
4. Puchois, P., Kandoussi, A., Fievet, P., Fourrier, J. L., Bertrand, M., Koren, E. and Fruchart, J. C. (1987) Apolipoprotein A-I containing lipoproteins in coronary artery disease, Atherosclerosis 68, 35-40
5. Van der Steeg, W. A., Holme, I., Boekholdt, S. M., Larsen, M. L., Lindahl, C., Stroes, E. S. G., Tikkanen, M. J., Wareham, N. J., Faergeman, O., Olsson, A. G. et al. (2008) High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: The IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol. 51, 634-642
6. Blanco-Vaca, F. Escolà-Gil J. C., Martín-Campos, J. M. and Julve, J. (2001) Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J. Lipid Res. 42, 1727-1739
7. Warden, C. H., Hedrick, C. C., Qiao, J. H., Castellani, L. W. and Lusis, A. J. (1993) Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 261, 469-471
8. Escolà-Gil, J. C., Marzal-Casacuberta, À., Julve-Gil, J., Ishida, B. Y., Ordóñez-Llanos, J., Chan, L., González-Sastre, F. and Blanco-Vaca, F. (1998) Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. J. Lipid Res. 39, 457-462
9. Birjmohun, R. S., Dallinga-Thie, G. M., Kuivenhoven, J. A., Stroes, E. S. G., Otvos, J. D., Wareham, N. J., Luben, R., Kastelein, J. J. P., Khaw, K. T. and Boekholdt, S. M. (2007) Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation 116, 2029-2035
10. Buring, J. E., O'Connor, G. T., Goldhaber, S. Z., Rosner, B., Herbert, P. N., Blum, C. B., Breslow, J. L. and Hennekens, C. H. (1992) Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 85, 22-29
11. Roselli della Rovere, G., Lapolla, A., Sartore, G., Rossetti, C., Zambon, S., Minicuci, N., Crepaldi, G., Fedele, D. and Manzato, E. (2003) Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients: a nine-year follow-up study. Nutr. Metab. Cardiovasc. Dis. 13, 46-51
12. Syvanne, M., Kahri, J., Virtanen, K. S. and Taskinen, M. R. (1995) HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation 92, 364-370
13. Sweetnam, P. M., Bolton, C. H., Downs, L. G., Durrington, P. N., Mackness, M. I., Elwood, P. C. and Yarnell, J. W. (2000) Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur. J. Clin. Invest. 30, 947-956
14. Lamarche, B., Rashid, S. and Lewis, G. F. (1999) HDL metabolism in hypertriglyceridemic states: an overview. Clin. Chim. Acta 286, 145-161
15. Taskinen, M. R. (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46, 733-749
16. Ji, J., Watts, G. F., Johnson, A. G., Chan, D. C., Ooi, E. M. M., Rye, K. A., Serone, A. P. and Barrett, P. H. R. (2006) High-density lipoprotein transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J. Clin. Endocrinol. Metab. 91, 973-979
17. Van Gaal, L. F., Wauters, M. A. and De Leeuw, I. H. (1997) The beneficial effects of modest weight loss on cardiovascular risk factors. Int. J. Obes. Relat. Metab. Disord. 21, S5-S9
18. Riches, F. M., Watts, G. F., Hua, J., Stewart, G. R., Naoumova, R. P. and Barrett, P. H. R. (1999) Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J. Clin. Endocrinol. Metab. 84, 2854-2861
19. Ng, T. W., Watts, G. F., Barrett, P. H. R., Rye, K. A. and Chan, D. C. (2007) Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: association with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care 30, 2945-2950
20. Watts, G. F., Chan, D. C., Barrett, P. H. R., Hua, J. and Swong, S. (2003) Adipose tissue compartments and the kinetics of very-low-density-lipoprotein B-100 in overweight/obese men. Obesity Res. 11, 152-159
21. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F. and Turner, R. C. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419
22. Mori, T. A., Croft, K. D. and Puddey, I. B. (1996) Analysis of native and oxidized low-density lipoprotein oxysterols using gas chromatography-mass spectrometry with selective ion monitoring. Redox Rep. 2, 25-31
23. Vélez-Carrasco, W., Lichtenstein, A. H., Welty, F. K., Li, Z., Lamon-Fava, S., Dolnikowski, G. G. and Schaefer, E.J. (1999) Dietary restriction of saturated fat and cholesterol decreases HDL apoA-I secretion. Arterioscler. Thromb. Vasc. Biol. 19, 918-924
24. Brinton, E. A., Eisenberg, S. and Breslow, J. L. (1990) A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J. Clin. Invest. 85, 144-151
25. Desroches, S., Paradis, M. E., Pérusse, M., Archer, W. R., Bergeron, J., Couture, P., Bergeron, N. and Lamarche, B. (2004) Apolipoprotein A-I, A-II, and VLDL-B-100 metabolism in men: comparison of a low-fat diet and a high-monounsaturated fatty acid diet. J. Lipid Res. 45, 2331-2338
26. Watts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F. and Johnson, A. G. (2003) Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52, 803-811
27. Chan, D. C., Watts, G. F., Nguyen, M. N. and Barrett, P. H. R. (2006) Factorial study of the effect of n - 3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and apoA-II in men with abdominal obesity. Am. J. Clin. Nutr. 84, 37-43
28. Chan, D. C., Nguyen, M. N., Watts, G. F. and Barrett, P. H. (2008) Plasma apolipoprotein C-III transport in central obese men: association with low density lipoprotein apolipoprotein B and high-density lipoprotein metabolism. J. Clin. Endocrinol. Metab. 93, 557-564